Clinical Trial Update: Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated thalidomide, doxorubicin, and dexamethasone in patients with untreated stage II or stage III multiple myeloma, and the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Doxorubicin (doxorubicin)
• Thalidomide (thalidomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED